Phreesia (NYSE:PHR) Sets New 52-Week Low Following Weak Earnings

Shares of Phreesia, Inc. (NYSE:PHR) hit a new 52-week low during trading on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $8.23 and last traded at $8.0690, with a volume of 261246 shares. The stock had previously closed at $11.41.

The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.11) EPS.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

Wall Street Analyst Weigh In

PHR has been the topic of a number of recent analyst reports. DA Davidson dropped their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Barclays reduced their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, December 16th. Needham & Company LLC dropped their target price on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. Wall Street Zen downgraded Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Insider Activity at Phreesia

In other news, insider David Linetsky sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the transaction, the insider directly owned 231,723 shares of the company’s stock, valued at $3,941,608.23. This represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $107,452.17. Following the sale, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. The trade was a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 70,358 shares of company stock worth $1,123,569 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Phreesia by 8.3% in the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock valued at $134,177,000 after buying an additional 437,462 shares during the period. New York State Common Retirement Fund grew its stake in shares of Phreesia by 727.1% during the 3rd quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock worth $3,219,000 after acquiring an additional 120,309 shares during the period. Squarepoint Ops LLC grew its stake in shares of Phreesia by 243.6% during the 2nd quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after acquiring an additional 71,553 shares during the period. Greenhouse Funds LLLP increased its holdings in Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after acquiring an additional 557,265 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in Phreesia by 1,065.9% in the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock valued at $13,043,000 after acquiring an additional 506,954 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Stock Down 27.0%

The firm has a market capitalization of $502.28 million, a P/E ratio of 277.70 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a 50 day moving average of $12.36 and a 200-day moving average of $17.57.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.